Relmada Therapeutics/RLMD

$4.00

-6.97%
-
1D1W1MYTD1YMAX

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.

Ticker

RLMD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sergio Traversa

Employees

20

Headquarters

Coral gables, United States

RLMD Metrics

BasicAdvanced
$141.22M
Market cap
-
P/E ratio
-$3.28
EPS
0.20
Beta
-
Dividend rate
$141.22M
0.1992
$7.22
$2.36
212.42K
7.996
-78.89%
-87.51%
-87.51%
1.65
1.654
38.14%

What the Analysts think about RLMD

Analyst Ratings

Majority rating from 5 analysts.
Hold

Price Targets

Average projection from 4 analysts.
172% upside
High $25.00
Low $3.00
$4.00
Current price
$10.88
Average price target

RLMD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-25.1M
14.09%
Profit margin
0%
-

RLMD Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.2%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.87
-$0.84
-$0.73
-$0.84
-
Expected
-$0.89
-$0.90
-$0.91
-$0.83
-$0.85
Surprise
-2.16%
-6.34%
-20.04%
1.2%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Relmada Therapeutics stock?

Relmada Therapeutics (RLMD) has a market cap of $120.7M as of April 21, 2024.

What is the P/E ratio for Relmada Therapeutics stock?

The price to earnings (P/E) ratio for Relmada Therapeutics (RLMD) stock is 0 as of April 21, 2024.

Does Relmada Therapeutics stock pay dividends?

No, Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Relmada Therapeutics dividend payment date?

Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders.

What is the beta indicator for Relmada Therapeutics?

Relmada Therapeutics (RLMD) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Relmada Therapeutics stock price target?

The target price for Relmada Therapeutics (RLMD) stock is $10.88, which is 172% above the current price of $4. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Relmada Therapeutics stock

Buy or sell Relmada Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing